NEWS

Vesalio Secures Class A Funding

Nashville, TN, June 2, 2021 Vesalio announces it has successfully secured a Class A financing round. The proceeds will be utilized to support the ongoing US IDE stroke study, establish US infrastructure, expand its innovative product portfolio, and scale international business. This round, led by Solas BioVentures, included participation from both new and existing investors.

Endovascular bail-out after massive rupture

A Case of Ruptured Brain Stem AVM Causing vessel Perforation

Vesalio Initiates FDA IDE Stroke Study

Nashville, TN, May 11, 2021 Vesalio announces another key milestone to support entry into the US neurovascular thrombectomy market. Enrollment has commenced in the Vesalio CLEAR(1) acute ischemic stroke FDA IDE clinical trial utilizing the NeVaTM thrombectomy technology platform. With twenty participating stroke treatment centers, enrollment is expected to be completed in early 2022.

Left anterior condylar confluence DAVF

Perflow Medical Expands Product Portfolio with First Clinical Use of the...

NETANYA, Israel, April 29, 2021 - Perflow Medical, a private, Israeli-based innovator for neurovascular treatments, today announced the first successful clinical use of the Stream™17 Dynamic Neuro-Thrombectomy Net, a lower profile device designed for more tortuous anatomy, to effectively treat hemorrhagic and ischemic stroke patients.

Vesalio Attains Key FDA Clinical Study Milestone

Nashville, TN, April 28, 2021, Vesalio announces it has accomplished a key FDA IDE study milestone to support entry into the US neurovascular market. Enrollment in the VITAL1 clinical trial, assessing the company’s NeVa VS™ technology in the treatment of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH), has been completed.

Pseudo-occlusion and two exceptions to the rule